REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) has announced a webcast to discuss the AFFINITY DUCHENNE® pivotal program and present first functional data from their Phase I/II study of RGX-202, a next-generation gene therapy for Duchenne muscular dystrophy. The webcast, scheduled for November 18, 2024, will feature principal investigator Dr. Aravindhan Veerapandiyan from Arkansas Children's Hospital and Dr. Michael Kelly, Chief Scientific Officer of CureDuchenne.

The findings will also be presented at the American Society of Gene and Cell Therapy and Muscular Dystrophy Association 2024 Breakthroughs conference in Chicago on November 19, 2024.

-       Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE^® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne

ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE^® pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital, and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne.

Webcast details
Title: AFFINITY DUCHENNE Trial of RGX-202: Pivotal Program and Interim Clinical Data
Date/Time: Monday, November 18, 2024, at 8:00 a.m. EST 
Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

These updates will also be presented at the American Society of Gene and Cell Therapy and Muscular Dystrophy Association 2024 Breakthroughs in Muscular Dystrophy conference November 19, 2024, in Chicago.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-pivotal-program-and-first-functional-data-from-the-affinity-duchenne-trial-of-rgx-202-302305167.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present the AFFINITY DUCHENNE trial data?

REGENXBIO will present the AFFINITY DUCHENNE trial data during a webcast on November 18, 2024, at 8:00 a.m. EST, followed by a presentation at the Breakthroughs in Muscular Dystrophy conference on November 19, 2024.

What type of data will REGENXBIO (RGNX) present from the RGX-202 trial?

REGENXBIO will present the first functional data from their Phase I/II study of RGX-202, their next-generation gene therapy for Duchenne muscular dystrophy.

Who are the key speakers at REGENXBIO's (RGNX) AFFINITY DUCHENNE webcast?

The webcast will feature Dr. Aravindhan Veerapandiyan, principal investigator from Arkansas Children's Hospital, and Dr. Michael Kelly, Chief Scientific Officer of CureDuchenne.